Kestra Medical Technologies, Ltd. KMTS
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- +0.41%
- 1 year
- +3.10%
5D -0.56 (-1.92%)
- Market cap
- 1.59B
- Revenue (ttm)
- 106.73M
- Profit margin
- -140.43%
- EPS (ttm)
- -2.67
- Shares out
- 59.56M
- Forward P/E
- -12.96
- YTD return
- +0.41%
- 1-year return
- +3.10%
- 50-day average
- 27.57
- Volume
- 382.49K
- Avg volume
- 417.15K
- Open
- 28.48
- Previous close
- 28.29
- Day's range
- 26.36 – 28.48
- 52-week range
- 17.34 – 31.99
- Analysts
- Strong Buy
- Price target
- 31.13 (+16.9%)
- Earnings date
- Dec 10, 2026
Key statistics
- 200-day average
- 24.13
- Enterprise value
- 1.56B
- Price / sales
- 14.86
- Price / book
- 7.10
- Revenue growth
- 59.90%
- Free cash flow
- -72.03M
- Total cash
- 198.91M
- Total debt
- 76.45M
- Return on equity
- -73.73%
- Short % of float
- 14.62%
Fundamental scorecard
6 of 25 checks passed on KMTS’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jul 31, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 28.00
- Target (mean)
- 31.13
- Target (high)
- 34.00
- Strong buy2
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Dec 10, 2026
Expected Dec 10, 2026. Consensus EPS estimate -0.605.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 10, 2026 | Oct 31, 2026 | -0.60556 | — | — | — |
| Sep 14, 2026 | Jul 31, 2026 | -0.61586 | -0.75 | -0.13 | -21.78% |
| Jul 14, 2026 | Apr 30, 2026 | -0.59 | -0.67 | -0.08 | -13.56% |
| Mar 17, 2026 | Jan 31, 2026 | -0.60 | -0.61 | -0.01 | -1.67% |
| Dec 11, 2025 | Oct 31, 2025 | -0.59411 | -0.62 | -0.03 | -4.36% |
| Sep 11, 2025 | Jul 31, 2025 | -0.66 | -0.46 | +0.20 | +30.30% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Evercore ISI Group | init | — | Outperform |
| Sep 15, 2026 | BTIG | reit | Buy | Buy |
| Sep 2, 2026 | BTIG | reit | Buy | Buy |
| Aug 10, 2026 | JP Morgan | init | — | Overweight |
| Jul 21, 2026 | Oppenheimer | init | — | Perform |
| Jul 15, 2026 | BTIG | main | Buy | Buy |
About Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- kestramedical.com
News
Kestra Medical Technologies Announces Publication Of Primary Results From Its ASSURE WCD Study In The Journal Of Cardiovascular Electrophysiology; ACE-PAS Enrolled 21,612 Patients Across 35 U.S. States And Met Both Primary Safety And Effectiveness Endpoints
Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology Evercore ISI Group Initiates Coverage On Kestra Medical Techs with Outperform Rating, Announces Price Target of $34
Your note
Sign in to keep a note on KMTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHEN RAYMOND W | Director | Sale | Sep 29, 2026 | 54,790 |
| FORD ALFRED J. JR | Officer | Sale | Aug 3, 2026 | 99,564 |
| HANLEY CONOR | Director | Stock Award(Grant) | Sep 8, 2026 | 13,489 |
| KWO ELIZABETH | Director | Sale | Sep 20, 2026 | 14,116 |
| LADONE MARY KAY | Director | Stock Award(Grant) | Sep 8, 2026 | 44,724 |
| MAHBOOB VASEEM | Chief Financial Officer | Sale | Oct 28, 2026 | 60,609 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Investors Llc | 42.26% | 25,172,338 | 670.34M | Sep 29, 2026 |
| FMR, LLC | 10.00% | 5,957,701 | 158.65M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 8.97% | 5,342,837 | 142.28M | Sep 29, 2026 |
| Andera Partners | 4.58% | 2,728,679 | 72.66M | Sep 29, 2026 |
| Yu Fan | 3.83% | 2,282,519 | 60.78M | Sep 29, 2026 |
| Blackrock Inc. | 3.75% | 2,231,097 | 59.41M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price New Horizons Fund, Inc. | 4.10% | 2,443,527 | 65.07M | Jun 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 2.30% | 1,368,136 | 36.43M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 1.81% | 1,079,460 | 28.75M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.81% | 1,080,000 | 28.76M | Sep 29, 2026 |
| Fidelity Select PORT.s-Select Medical Technology and Devices PORT. | 1.75% | 1,040,000 | 27.70M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.56% | 927,188 | 24.69M | Jun 29, 2026 |
